Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review explores the efficacy and safety of treatments for dissecting cellulitis of the scalp, revealing a predominance of case reports and series, and concludes that randomized controlled trials are needed for better evidence-based therapies.

This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.

This study reviews the efficacy and safety of advanced therapies like TNFα inhibitors and IL-17/IL-23 inhibitors for dissecting cellulitis of the scalp, finding TNFα inhibitors particularly effective for severe or refractory cases, although prospective validation is needed for early intervention benefits.

This review observed that semaglutide may have therapeutic benefits for skin conditions like psoriasis and hidradenitis suppurativa, but reports of adverse skin reactions exist, indicating the need for further research to understand its safety and efficacy in dermatology.

This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.

This review highlights that while pharmacotherapy, including biological agents, provides varying but often partial control of hidradenitis suppurativa depending on disease severity, significant challenges and high relapse rates persist, necessitating further research for more effective treatments.

This review explores treatment options for HS in the US and identifies how social disparities impact access to care, but it reports no new clinical findings.

This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.

This review highlights recent advances in dermatology, including innovations in skin cancer treatments, acne and psoriasis management, trends in cosmetic procedures, and the impact of telemedicine, emphasizing ongoing research's role in enhancing patient care and outcomes.

This research highlights advancements in understanding and treating psoriasis, finding that targeted therapies like IL-17 and IL-23 inhibitors show promise, but challenges such as adverse events, treatment resistance, and the need for personalized approaches remain.

This study suggests that IL-33 promotes hair follicle changes and T cell infiltration in psoriatic mice and humans, contributing to psoriatic alopecia.

This study found that patients with chronic kidney disease-associated pruritus had elevated serum levels of interleukin 31, suggesting a possible role of this cytokine in the condition.

This handbook of dermatology provides a comprehensive practical manual for dermatologists, but reports no new research findings.

In this study, botulinum toxin type A injections reduced the severity of treatment-resistant scalp psoriasis in more patients compared to placebo over a 12-week period.

The document lists various dermatology topics, treatments, and diagnostic methods.

The abstract discusses the multidisciplinary nature and advancement of dermatology and aesthetic procedures within the health sciences, emphasizing the integration of diagnostic, corrective, preventive, and therapeutic approaches, but does not provide specific study results.

In this case report, secukinumab therapy for spondyloarthritis was associated with the development of alopecia areata in a 46-year-old woman, which improved after discontinuing the medication.

This study found that among anti-TNF-α agents, certolizumab is the least likely to cause paradoxical reactions such as psoriatic alopecia and appears to be an effective and safe option for managing psoriasis and PsA while minimizing these risks.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.

Upadacitinib effectively treats pyoderma gangrenosum.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

This case report describes regression of hidradenitis suppurativa lesions in two patients after 16 weeks of adalimumab treatment.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This study reported that belimumab helped over 40% of active systemic lupus erythematosus patients achieve low disease activity, with more than 20% able to stop glucocorticoids completely.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This study found that nonobese women with idiopathic hirsutism exhibited lower nitrite/nitrate concentrations and higher fibrinogen levels compared to control subjects, but these were similar to levels in women with polycystic ovary syndrome.